Mind the Gap: Persado Study Highlights Missed Opportunities for Travel Marketers
While consumers are prioritizing travel again, less than 20% are influenced to book by marketing campaigns…
Social Media
Stratasys to Combine with Desktop Metal in Approximately $1.8 Billion All-Stock Transaction
Merger Creates a Next-Generation Additive Manufacturing Company Delivering Industrial Polymer, Metal, Sand and Ceramic Solutions…
Mithra – Letter to Shareholders and Corporate Update
Letter to Shareholders and Corporate Update Access to EUR15 million under amended deal Donesta® U.S….
Mithra – Letter to Shareholders and Corporate Update
Letter to Shareholders and Corporate Update Access to EUR15 million under amended deal Donesta® U.S….
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity…
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
Webcast to be held on Monday, June 5, 2023 at 8:00 a.m. ET WALTHAM, Mass….
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
Webcast to be held on Monday, June 5, 2023 at 8:00 a.m. ET WALTHAM, Mass….
Clearview Social Introduces Artificial Intelligence Technology to Elevate Professional Firms’ Social Media Marketing Initiatives
‘Social Shuffle AI’ taps ChatGPT to generate social media content right within the Clearview Social…
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant…
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the…
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells,…
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with…
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with…
PureVPN Marks 16th Anniversary By Becoming 4x More Secure
BOSTON–(BUSINESS WIRE)–Committed to enhancing the online safety of its users, PureVPN – a leading virtual…
CORRECTING and REPLACING The Futurum Group Pioneers With Generative AI, Introduces World’s First ‘AI Analyst’ in B2B Space
Debuted as ‘FuturumAI’, services to include three Generative AI Services for world’s tech companies Beta…
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for…
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® (alirocumab) TARRYTOWN, N.Y., May 18,…
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe…
Avicanna Announces Results of Annual General and Special Meeting and Provides Corporate Update
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES….
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo,…